|
AirSculpt Technologies, Inc. (AIRS) DCF -Bewertung
US | Healthcare | Medical - Care Facilities | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
AirSculpt Technologies, Inc. (AIRS) Bundle
Explore AirSculpt Technologies, Inc. (AIRS) Finanzielle Aussichten mit unserem benutzerfreundlichen DCF-Taschenrechner! Geben Sie Ihre Projektionen für Wachstum, Margen und Kosten ein, um den inneren Wert von AirSculpt Technologies, Inc. (AIRS) zu berechnen und Ihre Anlageentscheidungen zu informieren.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41.2 | 62.8 | 133.3 | 168.8 | 195.9 | 291.4 | 433.3 | 644.5 | 958.5 | 1,425.5 |
| Revenue Growth, % | 0 | 52.21 | 112.4 | 26.61 | 16.07 | 48.72 | 48.72 | 48.72 | 48.72 | 48.72 |
| EBITDA | 5.6 | 15.7 | 23.0 | 3.5 | 19.7 | 39.7 | 59.0 | 87.7 | 130.5 | 194.0 |
| EBITDA, % | 13.64 | 24.97 | 17.29 | 2.08 | 10.07 | 13.61 | 13.61 | 13.61 | 13.61 | 13.61 |
| Depreciation | 5.0 | 5.6 | 6.6 | 8.1 | 10.3 | 21.0 | 31.2 | 46.4 | 69.0 | 102.6 |
| Depreciation, % | 12.03 | 8.99 | 4.95 | 4.78 | 5.23 | 7.19 | 7.19 | 7.19 | 7.19 | 7.19 |
| EBIT | .7 | 10.0 | 16.5 | -4.5 | 9.5 | 18.7 | 27.8 | 41.3 | 61.5 | 91.5 |
| EBIT, % | 1.61 | 15.98 | 12.34 | -2.69 | 4.84 | 6.42 | 6.42 | 6.42 | 6.42 | 6.42 |
| Total Cash | 5.1 | 10.4 | 25.3 | 9.6 | 10.3 | 34.3 | 51.1 | 75.9 | 112.9 | 168.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | 2.8 | 1.9 | 1.6 | 2.3 | 3.4 | 5.1 | 7.6 |
| Account Receivables, % | 0 | 0 | 0 | 1.68 | 0.99073 | 0.53358 | 0.53358 | 0.53358 | 0.53358 | 0.53358 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payable | 2.1 | 1.1 | 2.7 | 3.8 | 3.9 | 7.7 | 11.4 | 17.0 | 25.2 | 37.5 |
| Accounts Payable, % | 5.13 | 1.74 | 2 | 2.28 | 2 | 2.63 | 2.63 | 2.63 | 2.63 | 2.63 |
| Capital Expenditure | -4.4 | -3.7 | -7.1 | -12.9 | -9.9 | -20.2 | -30.1 | -44.7 | -66.5 | -98.9 |
| Capital Expenditure, % | -10.76 | -5.88 | -5.34 | -7.65 | -5.06 | -6.94 | -6.94 | -6.94 | -6.94 | -6.94 |
| Tax Rate, % | 249.4 | 249.4 | 249.4 | 249.4 | 249.4 | 249.4 | 249.4 | 249.4 | 249.4 | 249.4 |
| EBITAT | 1.5 | 7.6 | 16.0 | -5.9 | -14.2 | 13.9 | 20.7 | 30.8 | 45.9 | 68.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 4.2 | 8.5 | 17.0 | -12.4 | -12.9 | 18.8 | 24.8 | 36.9 | 54.9 | 81.6 |
| WACC, % | 10.61 | 10.17 | 10.55 | 10.61 | 8.79 | 10.15 | 10.15 | 10.15 | 10.15 | 10.15 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 152.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 83 | |||||||||
| Terminal Value | 1,022 | |||||||||
| Present Terminal Value | 630 | |||||||||
| Enterprise Value | 783 | |||||||||
| Net Debt | 89 | |||||||||
| Equity Value | 694 | |||||||||
| Diluted Shares Outstanding, MM | 57 | |||||||||
| Equity Value Per Share | 12.22 |
What You Will Receive
- Comprehensive Financial Model: AirSculpt's actual data facilitates accurate DCF valuation.
- Complete Forecast Control: Modify revenue growth, margins, WACC, and other essential parameters.
- Real-Time Calculations: Automatic updates provide immediate results as you adjust inputs.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, allowing repeated application for in-depth forecasts.
Key Features
- Comprehensive DCF Calculator: Features both unlevered and levered DCF valuation models tailored for AirSculpt Technologies, Inc. (AIRS).
- WACC Calculator: Ready-to-use Weighted Average Cost of Capital sheet with adjustable parameters for precise calculations.
- Customizable Forecast Assumptions: Easily alter growth projections, capital expenditures, and discount rates.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for AirSculpt Technologies, Inc. (AIRS).
- Interactive Dashboard and Charts: Visual representations that condense key valuation metrics for straightforward analysis.
How It Works
- 1. Access the Model: Download and open the Excel template containing AirSculpt Technologies, Inc. (AIRS) preloaded data.
- 2. Adjust Key Inputs: Modify essential parameters such as growth rates, WACC, and capital expenditures.
- 3. Instant Result Generation: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Explore Different Scenarios: Evaluate various projections to understand diverse valuation results.
- 5. Make Informed Decisions: Present expert valuation analyses to bolster your strategic choices.
Why Choose AirSculpt Technologies, Inc. (AIRS)?
- Innovative Solutions: Cutting-edge technology for advanced body contouring procedures.
- Proven Results: High patient satisfaction rates backed by clinical studies.
- Expert Team: Skilled professionals dedicated to providing exceptional care.
- Minimally Invasive: Techniques designed to reduce recovery time and enhance comfort.
- Industry Leader: Recognized for excellence in cosmetic surgery and patient outcomes.
Who Should Use This Product?
- Medical Professionals: Enhance patient outcomes through advanced body contouring techniques.
- Healthcare Administrators: Evaluate the financial implications of adopting innovative surgical technologies.
- Consultants and Advisors: Offer clients informed insights into the benefits of AirSculpt Technologies for aesthetic procedures.
- Students and Educators: Utilize real-world applications to learn about advancements in cosmetic surgery.
- Beauty Industry Enthusiasts: Gain a deeper understanding of how modern technologies are transforming aesthetic practices.
What the Template Contains
- Pre-Filled Data: Includes AirSculpt Technologies' historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze AirSculpt Technologies' profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.